Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Differential Contribution of Active Site Residues in Substrate Recognition Sites 1 and 5 to Cytochrome P450 2C8 Substrate Selectivity and Regioselectivity

View Author Information
Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, SA 5042, Australia, and Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
Cite this: Biochemistry 2004, 43, 24, 7834–7842
Publication Date (Web):May 26, 2004
Copyright © 2004 American Chemical Society

    Article Views





    Other access options


    Selected active site residues in substrate recognition sites (SRS) 1 and 5 of cytochrome P450 2C8 (CYP2C8) were mutated to the corresponding amino acids present in CYP2C9 to investigate the contribution of these positions to the unique substrate selectivity and regioselectivity of CYP2C8. The effects of mutations, singly and in combination, were assessed from changes in the kinetics of paclitaxel 6α-hydroxylation, a CYP2C8-specific pathway, and the tolylmethyl and ring hydroxylations of torsemide, a mixed CYP2C9/CYP2C8 substrate. Within SRS1, the single mutation S114F abolished paclitaxel 6α-hydroxylation, while the I113V substitution resulted in modest parallel reductions in Km and Vmax. Mutations in SRS5 (viz., V362L, G365S, and V366L) reduced paclitaxel intrinsic clearance (Vmax/Km) by 88−100%. Torsemide is preferentially metabolized by CYP2C9, and it was anticipated that the mutations in CYP2C8 might increase activity. However, methyl and ring hydroxylation intrinsic clearances were either unchanged or decreased by the mutations, although hydroxylation regioselectivity was often altered relative to wild-type CYP2C8. The mutations significantly increased (28−968%) Km values for both torsemide methyl and ring hydroxylation but had variable effects on Vmax. The effects of the combined mutations in SRS1, SRS5, and SRS1 plus SRS5 were generally consistent with the changes produced by the separate mutations. Mutation of CYP2C8 at position 359 (S359I), a site of genetic polymorphism in CYP2C9, resulted in relatively minor changes in paclitaxel- and torsemide-hydroxylase activities. The results are consistent with multiple substrate binding orientations within the CYP2C8 active site and a differential contribution of active site residues to paclitaxel and torsemide binding and turnover.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

     This work was supported by a grant from the National Health and Medical Research Council of Australia.

     Flinders University and Flinders Medical Centre.


     Mahidol University.


     Corresponding author. E-mail:  [email protected]. Telephone:  61-8-82044131. Fax:  61-8-82045114.

    Cited By

    This article is cited by 23 publications.

    1. Yasuhiro Uno, Norie Murayama, Hiroshi Yamazaki. Novel Cytochrome P450 2C119 Enzymes in Cynomolgus and Rhesus Macaques Metabolize Progesterone, Diclofenac, and Omeprazole. Drug Metabolism and Disposition 2024, 52 (3) , 266-273.
    2. Jeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan. Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect. Pharmaceutical Research 2020, 37 (7)
    3. Tashinga E. Bapiro, Andy Sykes, Scott Martin, Michael Davies, James W. T. Yates, Matthias Hoch, Helen E. Rollison, Barry Jones. Complete Substrate Inhibition of Cytochrome P450 2C8 by AZD9496, an Oral Selective Estrogen Receptor Degrader. Drug Metabolism and Disposition 2018, 46 (9) , 1268-1276.
    4. Robert S. Foti, Philippe Diaz, Dominique Douguet. Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases. Journal of Enzyme Inhibition and Medicinal Chemistry 2016, 31 (sup2) , 148-161.
    5. Lushan Yu, Da Shi, Liping Ma, Quan Zhou, Su Zeng. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharmaceutics & Drug Disposition 2013, 34 (5) , 278-287.
    6. Nitsupa Wattanachai, Thomas M. Polasek, Tahlia M. Heath, Verawan Uchaipichat, Wongwiwat Tassaneeyakul, Wichittra Tassaneeyakul, John O. Miners. In vitro–in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. European Journal of Clinical Pharmacology 2011, 67 (8) , 815-824.
    7. Tianlei Ying, Fangfang Zhong, Zhong‐Hua Wang, Wei Li, Xiangshi Tan, Zhong‐Xian Huang. A Route to Novel Functional Metalloproteins via Hybrids of Cytochrome P450 and Cytochrome c. ChemBioChem 2011, 12 (5) , 707-710.
    8. Nobumitsu Hanioka, Kimiaki Matsumoto, Yoshiro Saito, Shizuo Narimatsu. Functional Characterization of CYP2C8.13 and CYP2C8.14: Catalytic Activities toward Paclitaxel. Basic & Clinical Pharmacology & Toxicology 2010, 107 (1) , 565-569.
    9. Lu Sun, Zhong-Hua Wang, Feng-Yun Ni, Xiang-Shi Tan, Zhong-Xian Huang. The Role of Ile476 in the Structural Stability and Substrate Binding of Human Cytochrome P450 2C8. The Protein Journal 2010, 29 (1) , 32-43.
    10. Alexander Seifert, Jürgen Pleiss. Identification of selectivity‐determining residues in cytochrome P450 monooxygenases: A systematic analysis of the substrate recognition site 5. Proteins: Structure, Function, and Bioinformatics 2009, 74 (4) , 1028-1035.
    11. Tai-Sung Lee. Reverse Conservation Analysis Reveals the Specificity Determining Residues of Cytochrome P450 Family 2 (CYP 2). Evolutionary Bioinformatics 2008, 4 , EBO.S291.
    12. Tímea Polgár, Dóra K. Menyhárd, György M. Keserű. Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets. Journal of Computer-Aided Molecular Design 2007, 21 (9) , 539-548.
    13. David J. Elliot, Suharjono, Benjamin C. Lewis, Elizabeth M. J. Gillam, Donald J. Birkett, Annette S. Gross, John O. Miners. Identification of the human cytochromes P450 catalysing the rate‐limiting pathways of gliclazide elimination. British Journal of Clinical Pharmacology 2007, 64 (4) , 450-457.
    14. S V Vormfelde, M Schirmer, M R Toliat, I Meineke, J Kirchheiner, P Nürnberg, J Brockmöller. Genetic variation at the CYP2C locus and its association with torsemide biotransformation. The Pharmacogenomics Journal 2007, 7 (3) , 200-211.
    15. Samuel L. Collom, Arvind P. Jamakhandi, Alan J. Tackett, Anna Radominska-Pandya, Grover P. Miller. CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling. Archives of Biochemistry and Biophysics 2007, 459 (1) , 59-69.
    16. Rasmus S. Pedersen, Per Damkier, Kim Brosen. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. British Journal of Clinical Pharmacology 2006, 62 (6) , 682-689.
    17. James J Cali, Dongping Ma, Mary Sobol, Daniel J Simpson, Susan Frackman, Troy D Good, William J Daily, David Liu. Luminogenic cytochrome P450 assays. Expert Opinion on Drug Metabolism & Toxicology 2006, 2 (4) , 629-645.
    18. Jian Guo, Dejan Nikolic, Lucas R. Chadwick, Guido F. Pauli, Richard B. van Breemen. IDENTIFICATION OF HUMAN HEPATIC CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF 8-PRENYLNARINGENIN AND ISOXANTHOHUMOL FROM HOPS ( HUMULUS LUPULUS L.). Drug Metabolism and Disposition 2006, 34 (7) , 1152-1159.
    19. Anja Henningsson, Sharon Marsh, Walter J. Loos, Mats O. Karlsson, Adam Garsa, Klaus Mross, Stephan Mielke, Lucia Viganò, Alberta Locatelli, Jaap Verweij, Alex Sparreboom, Howard L. McLeod. Association of CYP2C8, CYP3A4, CYP3A5 , and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel. Clinical Cancer Research 2005, 11 (22) , 8097-8104.
    20. Sok-Siya Bun, Sarah Giacometti, Rapha??lle Fanciullino, Joseph Ciccolini, Hot Bun, Claude Aubert. Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs. Anti-Cancer Drugs 2005, 16 (6) , 675-682.
    21. Hiroyuki Hichiya, Toshiko Tanaka-Kagawa, Akiko Soyama, Hideto Jinno, Satoru Koyano, Noriko Katori, Erika Matsushima, Shigehisa Uchiyama, Hiroshi Tokunaga, Hideo Kimura, Narihiro Minami, Masaaki Katoh, Kenji Sugai, Yu-ichi Goto, Tomohide Tamura, Noboru Yamamoto, Yuichiro Ohe, Hideo Kunitoh, Hiroshi Nokihara, Teruhiko Yoshida, Hironobu Minami, Nagahiro Saijo, Masanori Ando, Shogo Ozawa, Yoshiro Saito, Jun-ichi Sawada. FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP2C8 VARIANTS, G171S, R186X, R186G, K247R, AND K383N, FOUND IN A JAPANESE POPULATION. Drug Metabolism and Disposition 2005, 33 (5) , 630-636.
    22. J. Brian Houston, Aleksandra Galetin. Modelling atypical CYP3A4 kinetics: principles and pragmatism. Archives of Biochemistry and Biophysics 2005, 433 (2) , 351-360.
    23. Thomas M. Polasek, David J. Elliot, Benjamin C. Lewis, John O. Miners. Mechanism-Based Inactivation of Human Cytochrome P4502C8 by Drugs in Vitro. Journal of Pharmacology and Experimental Therapeutics 2004, 311 (3) , 996-1007.